In this account, the recent advances which have been made in asymmetric iridium-catalysed hydrogenation are reviewed. The first part focuses on our own studies of bicyclic pyridine–phosphinite ligands. These ligands have greatly enhanced the application range of asymmetric hydrogenation and, for the first time, have allowed highly enantioselective hydrogenation of simple, alkyl-substituted olefins and substituted furans. In the second part of this account, experimental and computational mechanistic studies are discussed. Whether the catalytic cycle proceeds via Ir(I)–Ir(III) intermediates or via Ir(III)–Ir(V) intermediates is still the subject of debate.
No takes yet. Share an insight, caveat, or question.
Roseblade et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: